Free tool
FAERS Monitor: Isovue-370
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020327 or its brand name (Isovue-370, Iopamidol). Reports on generic versions are filed under their own applications.
Reports
2,951
Serious
2,159
73% of reports
Hospitalization
1,055
Death reported
261
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- dyspnoea191
- urticaria191
- anaphylactic reaction186
- pruritus174
- nausea164
- contrast media reaction144
- no adverse event140
- vomiting122
- acute kidney injury115
- hypersensitivity110
- off label use93
- dizziness89
- erythema86
- cough81
- anaphylactic shock78
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 32 |
| 2005 | 36 |
| 2006 | 7 |
| 2007 | 20 |
| 2008 | 25 |
| 2009 | 23 |
| 2010 | 59 |
| 2011 | 82 |
| 2012 | 78 |
| 2013 | 129 |
| 2014 | 146 |
| 2015 | 149 |
| 2016 | 160 |
| 2017 | 203 |
| 2018 | 207 |
| 2019 | 282 |
| 2020 | 172 |
| 2021 | 193 |
| 2022 | 186 |
| 2023 | 140 |
| 2024 | 169 |
| 2025 | 185 |
| 2026 | 268 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,208 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| contrast media reactionSignal | 144 | 463.1 | 392.8 | 61,929 |
| anaphylactic reactionSignal | 186 | 24.1 | 20.9 | 4,087 |
| anaphylactic shockSignal | 78 | 21.6 | 17.4 | 1,512 |
| urticariaSignal | 191 | 8.1 | 7.1 | 1,196 |
| no adverse eventSignal | 140 | 5.5 | 4.7 | 516 |
| acute kidney injurySignal | 115 | 5.4 | 4.5 | 406 |
| hypersensitivitySignal | 110 | 4.2 | 3.5 | 270 |
| pruritusSignal | 174 | 3.2 | 2.8 | 270 |
| erythemaSignal | 86 | 3.0 | 2.4 | 112 |
| dyspnoeaSignal | 191 | 2.4 | 2.1 | 160 |
| coughSignal | 81 | 2.1 | 1.7 | 44 |
| vomiting | 122 | 1.8 | 1.6 | 48 |
| nausea | 164 | 1.5 | 1.3 | 26 |
| dizziness | 89 | 1.3 | 1.0 | 5 |
| off label use | 93 | 0.8 | 0.6 | 7 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.